Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqCM - Delayed Quote USD

Immix Biopharma, Inc. (IMMX)

Compare
1.6100
-0.0700
(-4.17%)
At close: April 1 at 4:00:00 PM EDT
1.6100
0.00
(0.00%)
After hours: April 1 at 4:05:12 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for IMMX

Recent News: IMMX

View More
Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis
GlobeNewswire last month
Several Insiders Invested In Immix Biopharma Flagging Positive News

Several Insiders Invested In Immix Biopharma Flagging Positive News
Simply Wall St. last month
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T
GlobeNewswire 2 months ago
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis
GlobeNewswire 3 months ago
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis
GlobeNewswire 3 months ago
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024

Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024
GlobeNewswire 3 months ago
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?

Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?
Simply Wall St. 3 months ago
Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media

Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media
GlobeNewswire 3 months ago
Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients

Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients
GlobeNewswire 4 months ago
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
GlobeNewswire 5 months ago
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
GlobeNewswire 6 months ago
View More

Related Tickers

KTTA Pasithea Therapeutics Corp.
1.2400
-4.62%
 
SPRC SciSparc Ltd.
0.2809
-5.74%
 
LIXT Lixte Biotechnology Holdings, Inc.
1.1950
-1.24%
 
ENSC Ensysce Biosciences, Inc.
2.5000
-2.34%
 
NRSN NeuroSense Therapeutics Ltd.
0.9088
-1.24%
 
REVB Revelation Biosciences, Inc.
2.6000
-1.14%
 
TRML Tourmaline Bio, Inc.
14.24
-6.38%
 
AZTR Azitra, Inc.
0.2900
-4.29%
 
NUVL Nuvalent, Inc.
68.00
-4.12%
 
APTO Aptose Biosciences Inc.
1.7100
-45.97%